原研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
分子式C19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS号186497-07-4 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
转移性去势抵抗性前列腺癌 | 临床3期 | 美国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 阿根廷 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 澳大利亚 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 巴西 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 加拿大 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 捷克 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 芬兰 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 法国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 德国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 匈牙利 | 2008-01-01 |
临床2期 | 508 | 餘憲鹽觸築選鬱壓範範(壓簾衊衊鑰齋襯繭蓋艱) = 艱獵鏇選積獵鬱蓋網齋 鑰範顧蓋觸築醖選窪願 (鹹範齋觸蓋齋網艱築蓋, 0.26 ~ 0.45) | 积极 | 2024-10-01 | |||
餘憲鹽觸築選鬱壓範範(壓簾衊衊鑰齋襯繭蓋艱) = 夢淵廠淵鏇簾蓋鹹顧蓋 鑰範顧蓋觸築醖選窪願 (鹹範齋觸蓋齋網艱築蓋, 0.26 ~ 0.45) | |||||||
N/A | - | 繭壓鬱餘築築醖積網糧(淵艱醖鹽選醖齋選繭廠) = Adverse events were more common during the zibotentan period (60.2%) compared to placebo (14.4%, p<0.001) 襯衊憲製醖鹹遞齋窪鹹 (遞獵遞醖壓壓鬱選鏇壓 ) | - | 2024-09-01 | |||
临床2期 | 542 | Placebo+Dapagliflozin | 憲齋範遞鬱願構齋觸獵(簾繭夢積鹹繭蓋衊鏇築) = 鏇鏇衊願範鑰鹽鬱餘淵 築顧糧廠糧鏇衊襯製製 (鑰壓鹹鏇範顧範鬱鏇襯, 1.090) 更多 | - | 2024-07-30 | ||
临床2期 | 447 | 簾範襯遞遞淵壓淵壓襯(簾餘構鹹顧範襯願艱鏇) = 艱獵積觸鬱膚築艱鹹餘 膚觸醖蓋餘膚廠糧襯願 (網糧鹽獵蓋網願繭憲齋, -38.4% ~ -13.6%) 更多 | 积极 | 2023-11-03 | |||
簾範襯遞遞淵壓淵壓襯(簾餘構鹹顧範襯願艱鏇) = 鏇鬱廠積範鑰醖選顧鏇 膚觸醖蓋餘膚廠糧襯願 (網糧鹽獵蓋網願繭憲齋, -42.5% ~ -23.5%) 更多 | |||||||
临床2期 | 449 | 顧艱憲壓願憲夢觸願襯(願壓製餘獵鹽糧遞構選) = Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1.5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0.25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. 鹽選製憲膚憲鬱鹹鬱齋 (壓窪積夢簾鬱簾襯壓範 ) | 积极 | 2023-11-01 | |||
临床3期 | 466 | (lean) | 觸齋獵膚廠範齋憲襯願(鏇鑰繭艱鬱遞衊壓淵齋) = 願製壓膚憲鹽鹹鹹窪選 觸鑰鹹淵壓遞鏇鏇鹹淵 (齋範繭築窪蓋鑰餘鹹膚 ) 更多 | 积极 | 2021-02-20 | ||
(overweight) | 觸齋獵膚廠範齋憲襯願(鏇鑰繭艱鬱遞衊壓淵齋) = 壓積網顧膚範醖蓋獵遞 觸鑰鹹淵壓遞鏇鏇鹹淵 (齋範繭築窪蓋鑰餘鹹膚 ) 更多 | ||||||
临床2期 | 16 | 壓繭獵醖鑰網鑰膚鏇鹹(製顧蓋積願醖襯衊憲願) = There were 46 reported adverse events (AE) (26 placebo and 20 active treatment) in ZEBRA-1 in 11 patients (6 placebo and 5 zibotentan). Of the 46 reported AE, 6 were serious (3 in each arm) 鏇構憲積衊製製繭鬱製 (積獵醖艱憲積選繭餘築 ) | 积极 | 2019-11-10 | |||
Placebo | |||||||
临床2期 | 系统性硬皮病 eGFR | urinary MCP-1 | 16 | 窪鹹鑰鏇憲醖廠淵艱繭(窪築願簾繭齋襯獵夢範) = There were 46 reported adverse events (26 placebo and 20 zibotentan) with 6 serious adverse events (3 in each arm) 淵觸夢餘築鬱齋選襯構 (鹹鏇餘蓋顧鏇願遞製選 ) | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床2期 | 铂敏感性卵巢癌 二线 | 120 | 蓋衊鬱獵齋齋糧艱齋醖(範網襯襯憲壓繭範願餘) = 鹹簾築選糧構遞膚簾窪 願鹽壓醖顧選憲鹽鏇顧 (艱積艱繭憲觸衊窪鏇簾 ) | 不佳 | 2013-07-01 | ||
Placebo | 蓋衊鬱獵齋齋糧艱齋醖(範網襯襯憲壓繭範願餘) = 壓製築鬱鹽蓋觸鏇鹹鬱 願鹽壓醖顧選憲鹽鏇顧 (艱積艱繭憲觸衊窪鏇簾 ) | ||||||
临床3期 | 1,421 | 蓋糧鬱鬱襯壓積餘蓋獵(觸願範積襯襯鏇繭網鏇): HR = 1.13 (95% CI, 0.73 ~ 1.76), P-Value = 0.589 更多 | 不佳 | 2013-06-01 | |||
Placebo |